Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1985 Sep;44(9):621–624. doi: 10.1136/ard.44.9.621

HLA antigens and toxic reactions to sodium aurothiopropanol sulphonate and D-penicillamine in patients with rheumatoid arthritis.

P Perrier, C Raffoux, P Thomas, J N Tamisier, M Busson, A Gaucher, F Streiff
PMCID: PMC1001721  PMID: 3876081

Abstract

One hundred and forty-one patients with rheumatoid arthritis treated with aurothiopropanol sulphonate or D-penicillamine, or both were examined for HLA antigens to investigate the genetic influence on the occurrence of different adverse reactions during therapy. All 13 patients possessing HLA-DR3 had toxic reactions. The relative risk for DR3 positives of developing skin eruptions or proteinuria was calculated to be 10.5 times and seven times respectively that of DR3 negatives. The incidence of DR7 antigen in 94 patients with toxic reactions was significantly decreased (11% compared with 28% in controls) suggesting a protective role for this antigen.

Full text

PDF
621

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bardin T., Dryll A., Debeyre N., Ryckewaert A., Legrand L., Marcelli A., Dausset J. HLA system and side effects of gold salts and D-penicillamine treatment of rheumatoid arthritis. Ann Rheum Dis. 1982 Dec;41(6):599–601. doi: 10.1136/ard.41.6.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bensen W. G., Moore N., Tugwell P., D'Souza M., Singal D. P. HLA antigens and toxic reactions to sodium aurothiomalate in patients with rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):358–361. [PubMed] [Google Scholar]
  3. Chalès G., Fauchet R., Pawlotsky Y., Gueguen M., Coutard J., Duval A., Pittie P. Les déterminants HLA-DR dans les rhumatismes inflammatoires chroniques. Rev Rhum Mal Osteoartic. 1983 Jun;50(7):525–531. [PubMed] [Google Scholar]
  4. Coblyn J. S., Weinblatt M., Holdsworth D., Glass D. Gold-induced thrombocytopenia. A clinical and immunogenetic study of twenty-three patients. Ann Intern Med. 1981 Aug;95(2):178–181. doi: 10.7326/0003-4819-95-2-178. [DOI] [PubMed] [Google Scholar]
  5. Dequeker J., Van Wanghe P., Verdickt W. A systematic survey of HLA-A,B,C and D antigens and drug toxicity in rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):282–286. [PubMed] [Google Scholar]
  6. Ford P. M. HLA antigens and drug toxicity in rheumatoid arthritis. J Rheumatol. 1984 Jun;11(3):259–261. [PubMed] [Google Scholar]
  7. Gran J. T., Husby G., Thorsby E. HLA DR antigens and gold toxicity. Ann Rheum Dis. 1983 Feb;42(1):63–66. doi: 10.1136/ard.42.1.63. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Karr R. W., Rodey G. E., Lee T., Schwartz B. D. Association of HLA-DRw4 with rheumatoid arthritis in black and white patients. Arthritis Rheum. 1980 Nov;23(11):1241–1245. doi: 10.1002/art.1780231102. [DOI] [PubMed] [Google Scholar]
  9. Majoos F. L., Klemp P., Meyers O. L., Briggs B. Gold therapy in rheumatoid arthritis. S Afr Med J. 1981 Jun 27;59(27):971–974. [PubMed] [Google Scholar]
  10. Nüsslein H. G., Jahn H., Lösch G., Guggenmoos-Holzmann I., Leibold W., Kalden J. R. Association of HLA-Bw35 with mucocutaneous lesions in rheumatoid arthritis patients undergoing sodium aurothiomalate therapy. Arthritis Rheum. 1984 Jul;27(7):833–836. doi: 10.1002/art.1780270718. [DOI] [PubMed] [Google Scholar]
  11. Panayi G. S., Wooley P., Batchelor J. R. Genetic basis of rheumatoid disease: HLA antigens, disease manifestations, and toxic reactions to drugs. Br Med J. 1978 Nov 11;2(6148):1326–1328. doi: 10.1136/bmj.2.6148.1326. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Speerstra F., Reekers P., van de Putte L. B., Vandenbroucke J. P., Rasker J. J., de Rooij D. J. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis. J Rheumatol. 1983 Dec;10(6):948–953. [PubMed] [Google Scholar]
  13. Stastny P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med. 1978 Apr 20;298(16):869–871. doi: 10.1056/NEJM197804202981602. [DOI] [PubMed] [Google Scholar]
  14. Wooley P. H., Griffin J., Panayi G. S., Batchelor J. R., Welsh K. I., Gibson T. J. HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med. 1980 Aug 7;303(6):300–302. doi: 10.1056/NEJM198008073030602. [DOI] [PubMed] [Google Scholar]
  15. van Riel P. L., Reekers P., van de Putte L. B., Gribnau F. W. Association of HLA antigens, toxic reactions and therapeutic response to auranofin and aurothioglucose in patients with rheumatoid arthritis. Tissue Antigens. 1983 Sep;22(3):194–199. doi: 10.1111/j.1399-0039.1983.tb01191.x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES